Glutathione c to ra t nhin trong c th chng ta bi gan
developed by Eli Lilly and Company, retatrutide has shown exceptional results in clinical research, with phase 2 trials demonstrating average weight loss of up to 24% over 48 weeks alongside improvements in insulin sensitivity, blood glucose regulation, lipid profiles, and reductions in visceral fat and liver fat, positioning it as one of the most promising next-generation obesity treatments currently under study
Comparative analysis showed that both RGD-GHK and sOtx2-GHK exhibited superior anti-oxidative and anti-apoptotic effects compared to the non-targeting peptide, GHK
They create a plan tailored specifically to you, which may include lifestyle recommendations, nutritional guidance, and, when appropriate, medication